[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Transthyretin-EMEA Market Status and Trend Report 2013-2023

March 2018 | 152 pages | ID: TFCBE6CF1DDMEN
MIReports Co., Limited

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Transthyretin-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Transthyretin industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Transthyretin 2013-2017, and development forecast 2018-2023
Main market players of Transthyretin in EMEA, with company and product introduction, position in the Transthyretin market
Market status and development trend of Transthyretin by types and applications
Cost and profit status of Transthyretin, and marketing status
Market growth drivers and challenges

The report segments the EMEA Transthyretin market as:

EMEA Transthyretin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa

EMEA Transthyretin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AG-10
ALN-TTRsc02
CRX-1008
EDE-1307
Inotersen Sodium
Others

EMEA Transthyretin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Familial Amyloid Neuropathies
Alzheimer's Disease
Cardomyopathy
Neuropathy
Others

EMEA Transthyretin Market: Players Segment Analysis (Company and Product introduction, Transthyretin Sales Volume, Revenue, Price and Gross Margin):
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Neurimmune Holding AG
Pfizer Inc
Prothena Corp Plc
Regeneron Pharmaceuticals Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF TRANSTHYRETIN

1.1 Definition of Transthyretin in This Report
1.2 Commercial Types of Transthyretin
  1.2.1 AG-10
  1.2.2 ALN-TTRsc02
  1.2.3 CRX-1008
  1.2.4 EDE-1307
  1.2.5 Inotersen Sodium
  1.2.6 Others
1.3 Downstream Application of Transthyretin
  1.3.1 Familial Amyloid Neuropathies
  1.3.2 Alzheimer's Disease
  1.3.3 Cardomyopathy
  1.3.4 Neuropathy
  1.3.5 Others
1.4 Development History of Transthyretin
1.5 Market Status and Trend of Transthyretin 2013-2023
  1.5.1 EMEA Transthyretin Market Status and Trend 2013-2023
  1.5.2 Regional Transthyretin Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Transthyretin in EMEA 2013-2017
2.2 Consumption Market of Transthyretin in EMEA by Regions
  2.2.1 Consumption Volume of Transthyretin in EMEA by Regions
  2.2.2 Revenue of Transthyretin in EMEA by Regions
2.3 Market Analysis of Transthyretin in EMEA by Regions
  2.3.1 Market Analysis of Transthyretin in Europe 2013-2017
  2.3.2 Market Analysis of Transthyretin in Middle East 2013-2017
  2.3.3 Market Analysis of Transthyretin in Africa 2013-2017
2.4 Market Development Forecast of Transthyretin in EMEA 2018-2023
  2.4.1 Market Development Forecast of Transthyretin in EMEA 2018-2023
  2.4.2 Market Development Forecast of Transthyretin by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types
  3.1.1 Consumption Volume of Transthyretin in EMEA by Types
  3.1.2 Revenue of Transthyretin in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
  3.2.1 Market Status by Types in Europe
  3.2.2 Market Status by Types in Middle East
  3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Transthyretin in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Transthyretin in EMEA by Downstream Industry
4.2 Demand Volume of Transthyretin by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Transthyretin by Downstream Industry in Europe
  4.2.2 Demand Volume of Transthyretin by Downstream Industry in Middle East
  4.2.3 Demand Volume of Transthyretin by Downstream Industry in Africa
4.3 Market Forecast of Transthyretin in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF TRANSTHYRETIN

5.1 EMEA Economy Situation and Trend Overview
5.2 Transthyretin Downstream Industry Situation and Trend Overview

CHAPTER 6 TRANSTHYRETIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Transthyretin in EMEA by Major Players
6.2 Revenue of Transthyretin in EMEA by Major Players
6.3 Basic Information of Transthyretin by Major Players
  6.3.1 Headquarters Location and Established Time of Transthyretin Major Players
  6.3.2 Employees and Revenue Level of Transthyretin Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 TRANSTHYRETIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Alnylam Pharmaceuticals Inc
  7.1.1 Company profile
  7.1.2 Representative Transthyretin Product
  7.1.3 Transthyretin Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals Inc
7.2 Arcturus Therapeutics Inc
  7.2.1 Company profile
  7.2.2 Representative Transthyretin Product
  7.2.3 Transthyretin Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics Inc
7.3 Ionis Pharmaceuticals Inc
  7.3.1 Company profile
  7.3.2 Representative Transthyretin Product
  7.3.3 Transthyretin Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals Inc
7.4 Neurimmune Holding AG
  7.4.1 Company profile
  7.4.2 Representative Transthyretin Product
  7.4.3 Transthyretin Sales, Revenue, Price and Gross Margin of Neurimmune Holding AG
7.5 Pfizer Inc
  7.5.1 Company profile
  7.5.2 Representative Transthyretin Product
  7.5.3 Transthyretin Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.6 Prothena Corp Plc
  7.6.1 Company profile
  7.6.2 Representative Transthyretin Product
  7.6.3 Transthyretin Sales, Revenue, Price and Gross Margin of Prothena Corp Plc
7.7 Regeneron Pharmaceuticals Inc
  7.7.1 Company profile
  7.7.2 Representative Transthyretin Product
  7.7.3 Transthyretin Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF TRANSTHYRETIN

8.1 Industry Chain of Transthyretin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF TRANSTHYRETIN

9.1 Cost Structure Analysis of Transthyretin
9.2 Raw Materials Cost Analysis of Transthyretin
9.3 Labor Cost Analysis of Transthyretin
9.4 Manufacturing Expenses Analysis of Transthyretin

CHAPTER 10 MARKETING STATUS ANALYSIS OF TRANSTHYRETIN

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications